This section reviews the current clinical trials evaluating the efficacy and safety of PCSK9 inhibition and anti-PD-1/PD-L1 immunotherapy in different types of cancer and discusses the potential benefits and challenges of this novel therapeutic approach. The gene discussed is PCSK9; the disease is cancer.